Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments. / (Record no. 1174)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 04342naa a22006497i 4500 |
| 001 - CONTROL NUMBER | |
| control field | UMUN-OA-20261005-MLS-032 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | local |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20261005174904.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr|||||||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 261005s2023 xx o u000 0 eng d |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1186/s12967-023-04292-3 |
| Source of number or code | doi |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (local)EuropePMC:PMC10327392 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | local |
| Language of cataloging | eng |
| Transcribing agency | local |
| 041 0# - LANGUAGE CODE | |
| Language code of text/sound track or separate title | eng |
| 100 0# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Gunjan Dagar |
| Relator term | author. |
| 245 10 - TITLE STATEMENT | |
| Title | Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments. / |
| Statement of responsibility, etc. | Gunjan Dagar; Ashna Gupta; Tariq Masoodi [and others]. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | [Place of publication not identified] : |
| Name of producer, publisher, distributor, manufacturer | BMC, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2023. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (1 article). |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 500 ## - GENERAL NOTE | |
| General note | The source lists 17 contributors; the first 12 names are recorded as access points. The complete source author list is retained in the catalogue manifest. |
| 500 ## - GENERAL NOTE | |
| General note | Publication type: Review article. |
| 500 ## - GENERAL NOTE | |
| General note | Linked open-access copy: published version. |
| 506 0# - RESTRICTIONS ON ACCESS NOTE | |
| Terms governing access | Open access; no subscription required for the linked open-access version. |
| Standardized terminology for access restriction | Unrestricted online access |
| Source of term | star |
| 520 3# - SUMMARY, ETC. | |
| Summary, etc. | Traditional cancer treatments use nonspecific drugs and monoclonal antibodies to target tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune system's T-cells to recognize and attack tumor cells. T-cells are isolated from patients and modified to target tumor-associated antigens. CAR-T therapy has achieved FDA approval for treating blood cancers like B-cell acute lymphoblastic leukemia, large B-cell lymphoma, and multiple myeloma by targeting CD-19 and B-cell maturation antigens. Bi-specific chimeric antigen receptors may contribute to mitigating tumor antigen escape, but their efficacy could be limited in cases where certain tumor cells do not express the targeted antigens. Despite success in blood cancers, CAR-T technology faces challenges in solid tumors, including lack of reliable tumor-associated antigens, hypoxic cores, immunosuppressive tumor environments, enhanced reactive oxygen species, and decreased T-cell infiltration. To overcome these challenges, current research aims to identify reliable tumor-associated antigens and develop cost-effective, tumor microenvironment-specific CAR-T cells. This review covers the evolution of CAR-T therapy against various tumors, including hematological and solid tumors, highlights challenges faced by CAR-T cell therapy, and suggests strategies to overcome these obstacles, such as utilizing single-cell RNA sequencing and artificial intelligence to optimize clinical-grade CAR-T cells. |
| 540 ## - TERMS GOVERNING USE AND REPRODUCTION NOTE | |
| Terms governing use and reproduction | Creative Commons Attribution. See the linked licence for the applicable terms. |
| Uniform Resource Identifier | <a href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</a> |
| 546 ## - LANGUAGE NOTE | |
| Language note | In English. |
| 588 0# - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Course allocation: B. Sc. Medical Laboratory Science. |
| 650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Tumor antigens |
| 650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Immunotherapy |
| 650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Hematological malignancy |
| 650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Solid tumor |
| 650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Cytokine Release Syndrome |
| 650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antigen Escape |
| 653 ## - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | B. Sc. Medical Laboratory Science |
| 653 ## - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | UMUN open access collection |
| 653 ## - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | hematology |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Review articles. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ashna Gupta |
| Relator term | author. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Tariq Masoodi |
| Relator term | author. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Sabah Nisar |
| Relator term | author. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Maysaloun Merhi |
| Relator term | author. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Sheema Hashem |
| Relator term | author. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ravi Chauhan |
| Relator term | author. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Manisha Dagar |
| Relator term | author. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Sameer Mirza |
| Relator term | author. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Puneet Bagga |
| Relator term | author. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Rakesh Kumar |
| Relator term | author. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ammira S Al-Shabeeb Akil |
| Relator term | author. |
| 773 0# - HOST ITEM ENTRY | |
| Title | Journal of translational medicine |
| Related parts | Vol. 21, no. 1, (2023), pages/article 449 |
| International Standard Serial Number | 1479-5876 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://europepmc.org/articles/PMC10327392">https://europepmc.org/articles/PMC10327392</a> |
| Link text | Read open-access publication |
| Public note | Open access. |
| Access status | 0 |
| 884 ## - DESCRIPTION CONVERSION INFORMATION | |
| Conversion process | Course selection and automated MARC21 enrichment from Europe PMC metadata. |
| Conversion date | 20261005 |
| Identifier of source metadata | https://europepmc.org/articles/PMC10327392 |
| Conversion agency | local |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Suppress in OPAC | No |
No items available.